{"url_path":"/sec/crbu/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1619856/0001619856-26-000043-index.html","accession_number":"0001619856-26-000043","cik":"0001619856","ticker":"CRBU","issuer_name":"Caribou Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1619856/0001619856-26-000043-index.html","primary_entity_key":"0001619856","primary_entity_name":"Caribou Biosciences, Inc."},"word_count":303,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 11, 2026, Caribou Biosciences, Inc. (the \"Company\") issued a press release announcing data from its ANTLER phase 1 clinical trial that evaluated vispacabtagene regedleucel (“vispa-cel;” formerly CB-010), an allogeneic anti-CD19 chimeric antigen receptor (\"CAR\")-T (“CAR-T”) cell therapy product candidate, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (“r/r B-NHL”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.\n\nAlso, on June 11, 2026, the Company issued a press release announcing longer follow-up data from the dose escalation portion of its ongoing CaMMouflage phase 1 trial evaluating CB-011, an allogeneic anti-B cell maturation antigen (“anti-BCMA”) CAR-T cell therapy product candidate, in patients with relapsed or refractory multiple myeloma (“r/r MM”). A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.\n\nThe Company will present the follow-up data from both clinical trials at oral presentations at the European Hematology Association (“EHA”) 2026 Annual Meeting in Stockholm, Sweden, with the vispa-cel data presentation on June 12, 2026, and the CB-011 data presentation on June 14, 2026.\n\nThe information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (“Securities Act”), regardless of any general incorporation language in any such filing or document, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act."}